049960.KQ Cell Biotech Co. Ltd

Healthcare Biotechnology KOSDAQ
13,120 KRW
Close of Oct 30, 2026
10,976 18,500
Market cap
KRW 101B
P/E
-
P/B
0.74x
ROE
13.1%
Dividend yield
3.04%
Fundamental score
2.3/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 049960.KQ undervalued?

Graham number

The Graham number of Cell Biotech Co. Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Cell Biotech Co. Ltd fundamental analysis

12 of 22 checks passed

ROE 1/2

Moderate return on equity (13.1%), between 10% and 20%.

ROA 1/1

Return on assets (12.4%) is above the industry median (-10.1%).

Profit Consistency 2/2

Profitable for 10 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Last year's EPS growth (-33.1%) is not above the 5-year average (26.8% a year).

Earnings Growth vs Industry 0/1

Last year's EPS growth (-33.1%) is below the industry median (4.8%).

Revenue Growth 1/2

Revenue grew 1.7% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 0/1

Debt is not reported.

Interest Coverage 1/1

EBIT is 1,589.7x against interest expense, well covered.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 1/1

Price to book (0.7x) is below the industry median (2.4x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 1/2

Dividend yield (3.0%) is above the bottom 25% of dividend payers in the market.

Dividend Stability 1/2

Dividends paid without a cut of more than 10% for 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 1/1

Payout ratio is 30.4%, covered by earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Cell Biotech Co. Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Cell Biotech Co. Ltd

Cell Biotech Co., Ltd., a biotechnology company, develops and sells lactic acid bacteria in South Korea. It also offers probiotic products under the Nutra DUOLAC, LACTOClear, and LAB2PRO brands. The company also exports its products to approximately 40 countries, including the United States, Europe, Japan, and China. Cell Biotech Co., Ltd. was founded in 1995 and is based in Gimpo-si, South Korea.

Full company profile